An indirect comparison of in?iximab versus adalimumab or golimumab for active ulcerative colitis

Archives of Medical Science

Volumn 12, Issue 5, 2016, Pages 1097-1109

  Kawalec, Pawel ^a   Pilc, Andrzej ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adalimumab; Biological Therapy; Golimumab; Indirect comparison; Infliximab; Systematic review; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; PLACEBO;

COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84989871834     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2016.58682     Document Type: Review

References (54)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-25.
2. Abraham C, Cho JH. Infammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
3. Kawalec P, Mikrut A, Łopuch S. A systematic review of the efectiveness of biological therapy for active moderate to severe ulcerative colitis: biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014; 29: 1159-70.
4. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the infammatory bowel diseases with time, based on systematic review. Gastroen-terology 2012; 142: 46-54.
5. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sand-born WJ. Ulcerative colitis. Lancet 2012; 380: 1606-19.
6. Danese S, Sans M, Fiocchi C. Infammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004; 3: 394-400.
7. Molodecky NA, Gilaad GK. Environmental risk factors for infammatory bowel disease. Gastroenterol Hepatol 2010; 6: 339-46.
8. Wang Y F, Ou-Yang Q, Xia B, et al. Multicenter case-control study of risk factors for ulcerative colitis in China. World J Gastroenterol 2013; 19: 1827-33.
9. Ananthakrishnan AN. Environmental risk factors for in-fammatory bowel disease. Gastroenterol Hepatol 2013; 9: 367-74.
10. Baumgart DC, Carding S.R. Infammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-40.
11. Prideaux L, Kamm MA, De Cruz P P, Chan FKL, Ng SC. In-fammatory bowel disease in Asia: a systematic review. J Gastroenterol Heaptol 2012; 27: 1266-80.
12. Sicilia B, Arribas F, Nerín J, López Miguel C, Vincente R, Gomollón. Risk factors for ulcerative colitis: a popula-tion-based, case-control study in Spain. J Crohns Colitis 2008; 2: 158-61.
13. Travis SPL, Stange E F, Lémann M, et al. European evidence-based Consensus on the management of ulcer-ative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
14. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of infammatory bowel disease in adults. Gut 2010; 60: 571-607.
15. Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroeneterology. Ulcerative colitis practice guidelines in adults: American College of Gastroeneterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
16. US Food and Drug Administration. 2013. Available from URL: http://www.fda.gov/.
17. European Medicine Agency. 2013. Available from URL: http://www.ema.europa.eu/.
18. Scallon BJ, Arevalo Moore M, Trinh H, Knight DM, Ghra-yeb J. Chimeric anti-TNF-alpha monoclonal anti-body cA2 binds recombinant transmembrane TNF-alpha and activates immune efector functions. Cytokine 1995; 7: 251-9.
19. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.
20. Chan AC, Carter PJ. Therapeutic antibodies for autoim-munity and infammation. Nat Rev 2010; 10: 301-16.
21. Bucher HC, Guyatt GH, Grifth LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.
22. Kawalec P, Mikrut A, Wisniewska N, Pilc A. Tumor necrosis factor-alpha antibodies (infiximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci 2013; 9: 765-79.
23. Moher D, Liberati A, Tetzlaf J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: e1000097.
24. Higgins J P, Green S. Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration and John Wiley 2008.
25. Gornet JM, Couve S, Hassani Z. Infiximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003; 18: 175-81.
26. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infiximab maintenance therapy for ulcerative colitis: the ACT-1 and-2 extension studies. Infamm Bowel Dis 2012; 18: 201-11.
27. Gustavsson A, Järnerot G, Hertervig E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infiximab study. Aliment Pharmacol Ther 2010; 32: 984-9.
28. Feagan BG, Reinisch W, Rutgeerts P, et al. The efects of infiximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802.
29. Järnerot G, Hertervig E, Friis-Liby I, et al. Infiximab as rescue therapy in severe to moderately severe ulcer-ative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
30. Probert CS, Hearing SD, Schreiber S, et al. Infiximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998-1002.
31. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalim-umab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
32. Suzuki Y, Motoya S, Hanai H, et al. Efcacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 2014; 49: 283-94.
33. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
34. Summary of Product Characteristics. Infiximab. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000240/WC500050888.pdf
35. Summary of Product Characteristics. Adalimumab. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Informa-tion/human/000481/WC500050870.pdf
36. Summary of Product Characteristics. Golimumab. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000992/WC500052368.pdf
37. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infiximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
38. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infiximab. Gastroenterology 2009; 137: 1250-60.
39. Sandborn WJ, van Assche G, Reinisch W, et al. Adalim-umab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gas-troenterology 2012; 142: 257-65.
40. Sandborn WJ, Colombel J F, D'Haens G, et al. One-year maintenance outcomes among patients with moder-ately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Therap 2013; 37: 204-13.
41. Feagan BG, Sandborn WJ, Lazar A, et al. Adalimumab therapy is associated with reduced risk of hospitaliza-tion in patients with ulcerative colitis. Gastroenterology 2014; 146: 110-8.
42. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
43. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.
44. A study of adalimumab in Japanese subjects with moder-ately to severely active ulcerative colitis. NCT00853099. Available from URL: https://clinicaltrials.gov/ct2/show/results/NCT00853099?term=NCT00853099&rank=1&-sect=Xh430156#outcome11.
45. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sand-born WJ. Ulcerative colitis. Lancet 2012; 380: 1606-19.
46. Assadsangabi A, Lobo AJ. Diagnosing and managing infammatory bowel disease. Practitioner 2013; 257: 13-8, 2.
47. Warner BW. Short-and long-term complications of col-ectomy. J Ped Gastroenterol Nutr 2009; 48 (Suppl. 2): 72-4.
48. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003; 238: 229-34.
49. Waljee A, Waljee J, Morris AM, Higgins PDR. Three-fold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55: 1575-80.
50. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2009; 3: CD005112.
51. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efcacy of biological therapies in infam-matory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-59.
52. th Annual European Congress. 2011.
53. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analy-sis. Ann Intern Med 2014; 160: 704-11.
54. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Kar-len P, Granno C et al. Infiximab as rescue therapy in severe to moderately severe ulcerative colitis: a random-ized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.